Investors spend a great deal of time looking for the next big winner. They often forget to ask a far more interesting question.

Who else wins if this trend becomes real?

Take the GLP-1 movement. GLP-1 drugs such as Ozempic, Wegovy and Zepbound were originally developed to help manage diabetes, but they have rapidly become some of the world’s most influential weight-loss medications, helping millions of people lose significant amounts of weight by reducing appetite and slowing digestion. Their impact is extending far beyond healthcare into industries as varied as food, airlines, apparel and consumer products. 

Recently, I came across an interesting observation. Victoria’s Secret’s stock has risen nearly 300% over the past year, and one of the explanations being discussed is that as more consumers lose weight through GLP-1 drugs, demand for apparel in categories like lingerie could receive an unexpected boost alongside improvements in the company’s own operating performance. 

Whether this explanation proves entirely correct is almost beside the point. The real lesson is about second-order thinking. The first-order effect is obvious: GLP-1 drug companies sell more medicines.

The second-order effect is where investing becomes fascinating. Who benefits because someone else succeeds? Which businesses quietly become stronger because consumer behavior changes? Which industries are being reshaped without ever appearing in the headline?

Great investors don’t merely study companies. They study consequences. This is because markets rarely reward only the business creating change. They often reward the businesses that quietly benefit from that change.

Sometimes, the most valuable investment opportunity isn’t the obvious winner. It’s the one standing just outside the spotlight, benefiting from a trend that everyone else is already watching.